The research area of Centauro Health Corporation (that includes OSI Health XXI and Biopraxis) has been working for years in the development of a suitable drug delivery system (DDS) for recombinant human epidermal growth factor (rhEGF). Lipid NP, more precisely, Nanostructured Lipid Carriers (NLC). in vitro experiments showed that the encapsulated rhEGF was able to promote cell proliferation in a higher extent than the free growth factor.
In addition, according to G. Gainza et al. (2014) wound healing studies carried out in db/db mice showed that 10 and 20 µg of rhEGF-NPs topically administered twice a week were more effective in promoting wound healing than 75 µg of free rhEGF administered intralesionally. The same results were observed by G. Gainza et al. (2015) in a more relevant preclinical model of wound healing, the porcine full-thickness excisional wound model.
On the other hand, wound infection is one of the major problems in skin grafting, especially in burns.
The use of lipid NPs to fight against Pseudomonas aeruginosa has revealed that nanoencapsulation enhanced the interaction between the biofilm-bearing colony and the antibiotic which also improved the security profile of well-known antibiotics. The lipid NPs selected for this project are nanostructured lipid carriers that could be coated with positive charges in order to increase their antibiotic activity.
To sum up, antibiotic nanoencapsulation can improve antibiotic activity and diminish drug toxicity, making it worth to explore it as an alternative to fight against resistant strains to ultimately improve bioengineered skin grafting. The possibility of infection of the artificial skin will be lessened by the use of antibiotic antibiotics-loaded NPs that will also tackle wound infection.